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ABSTRACT
During the development of methods for cancer
diagnosis and treatment, a vast amount of informa-
tion is generated. Novel cancer target proteins
have been identified and many compounds that
activate or inhibit cancer-relevant target genes
have been developed. This knowledge is based on
an immense number of experimentally validated
compound–target interactions in the literature, and
excerpts from literature text mining are spread over
numerous data sources. Our own analysis shows
that the overlap between important existing
repositories such as Comparative Toxicogenomics
Database (CTD), Therapeutic Target Database
(TTD), Pharmacogenomics Knowledge Base
(PharmGKB) and DrugBank as well as between our
own literature mining for cancer-annotated entries
is surprisingly small. In order to provide an easy
overview of interaction data, it is essential to inte-
grate this information into a single, comprehensive
data repository. Here, we present CancerResource,
a database that integrates cancer-relevant relation-
ships of compounds and targets from (i) our own
literature mining and (ii) external resources
complemented with (iii) essential experimental and
supporting information on genes and cellular
effects. In order to facilitate an overview of
existing and supporting information, a series of
novel information connections have been estab-
lished. CancerResource addresses the spectrum of
research on compound–target interactions in
natural sciences as well as in individualized
medicine; CancerResource is available at: http://
bioinformatics.charite.de/cancerresource/.
INTRODUCTION
Drug–protein interactions, or more generally, com-
pound–target interactions, are becoming increasingly
available for several layers of information according to
the different interests in biological, physical or pharmaco-
logical research. Consequently, a broad set of data
resources have been established and it is therefore not
easy for biological, chemical or pharmaceutical scientists
to deal with the often widespread and vast amounts of
data. However, it is straightforward to use the capability
of the Internet (1)—this includes up-to-date techniques
like Web Services (2) to access existing repositories—for
discovering compound–target interactions or determining
the druggability of genes.
CancerResource addresses the complexity of cancer
by covering not only a large but speciﬁc set of
compound–target interactions, experimental data and
supporting information but also by allowing individual
data to be processed for advanced analyses. This article
describes the database content and access to stored data
together with the usage of provided tools and tool com-
binations toward workﬂows.
CANCER LITERATURE AND TEXT MINING
In the past three decades, huge effort was spent on
research into cancer by an overwhelming number of
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extracted and made available in the Online Mendelian
Inheritance in Man (OMIM) (3) database. Multiple data
collections have arisen from the available repertoire of
knowledge on cancer by text mining. They are often
specialized like the Catalogue Of Somatic Mutations in
Cancer (COSMIC) (4), a web resource on mutations in
cancer genes that are detected in somatic tissues but also
in cultured tissue samples. Cancer-relevant genes have
been intensively studied and a fundamental model of
cancer was established by Hanahan and Weinberg (5).
On the other hand, the druggable genome (6) is, independ-
ent from the kind of disease, a set of proteins that are
regarded as possible drug target candidates.
Genome-scale targeting was identiﬁed originally by litera-
ture mining but has been successively developed by adding
other information resources (7). The overlap between both
perspectives, cancer-speciﬁc genes and druggable genome
entities, forms the theoretical background of the
CancerResource approach to the target genes; practically,
target genes are derived from literature mining
approaches.
Existing repositories like the Comparative
Toxicogenomics Database (CTD) (8), the Pharma-
cogenomics Knowledge Base (PharmGKB) (9), the
Therapeutic Target Database (TTD) (10) and the
DrugBank (11) provide rich information on interactions
of drugs (or drug-like compounds) with target genes or
proteins. After inspecting cancer-relevant compound–
target interactions, we found, surprisingly, that the data
sets of these resources are more or less disjunct (Table 1)
even when the results of the CancerResource literature
mining are considered. This analysis indicated that there
is need for integrating compound–target interactions from
external data sets into one source and hence stimulated the
creation of the CancerResource.
Cancer is often studied using somatic tissues, which are
cultured for research as tissue samples of various cancer
types and established as human standard cell lines. This
inhomogeneous spectrum of cancers is well characterized
and analyzed in large experimental studies investigating
gene expression or cell growth activity under the inﬂuence
of chemicals (12). This compound set of the National
Figure 1. Data integration in CancerResource with three levels of data information: compound–target interaction data- PubMed (14), CTD (8),
TTD (10), PharmGKB (9), DrugBank (11), PDB (18) -, experimental data - DTP at NCI (12), Connectivity Map (31) - and supporting information.
- KEGG (29), CORUM (24), ConsensusPathDB (23), SuperDrug (15). CancerResource can be explored with queries or user-deﬁned external data.
Table 1. Numbers of known interactions in external databases and
from the CancerResource literature text mining
Resource References Numbers of
compound–target
relationships
Uniqueness
Redundant Unique Degree (%)
External databases
CTD (8) 3875 3748 96
PharmGKB (9) 1307 1158 88
TTD (10) 282 163 58
DrugBank (11) 4949 4763 96
CancerResource
Literature mining (this article) 1122 992 88
CancerResource
Full data integration (this article) 11585 10824 93
Data from CTD, PharmGKB and TTD are ﬁltered according to
cancer-related disease annotations, data for DrugBank are unﬁltered.
Relationships unique to each approach include the CancerResource
literature mining result. The full integration result is presented addition-
ally. The degree of uniqueness reveals that the data sets are more or
less disjunct.
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and research on gene dysfunctions in cancer. A data inte-
gration tool like CancerResource demands extended func-
tionality. It is obvious that, similar to other compound–
target interaction resources presented in a toxicological
perspective (13), additional data such as experimental
results and further supporting information enhance the
knowledge of interactions together with features like: re-
lationship of genes in pathways, druggability of the genes
in the interactome, capability for user-deﬁned data
analyses and data mining and curation.
DATA INTEGRATION PROCEDURES AND
METHODS
Compound–target gene interactions: CancerResource text
mining
Compound–target relationships were automatically
detected by own literature text mining over 19 million
PubMed (14) abstracts using our vocabularies for drugs
and targets. The drug vocabulary was generated from
compounds having a cancer-related classiﬁcation with
respect to the Anatomical Therapeutic Chemical (ATC)
Classiﬁcation system via SuperDrug (15) or if the
compound and its synonymous name are in the NCI
compound set. The cancer relationship of a gene was
determined from annotations in cancer-related pathways
(see sub-section ‘KEGG pathways’) and the Gene
Ontology (GO) (16). Abstracts, titles and Medical
Subject Headings (MeSH) terms were converted into a
text index using the LingPipe (http://alias-i.com/lingpipe/
index.html) and the Lucene software packages (17). Both
vocabularies were searched against each indexed abstract
and the result was scored by an own rule-based validation
algorithm. After this automatic procedure and a subse-
quent ranking revealing about 8000 publications, a
manual revision of the hits followed resulting in about
900 highly signiﬁcant publications of direct interactions.
Compound–target gene interactions: more data
Important interaction resources are integrated in
CancerResource: CTD, TTD and PharmGKB. Sub-sets
of cancer-speciﬁc interactions are ﬁltered out according
to the cancer vocabulary that is inherent in the three re-
sources. The cancer-speciﬁc vocabulary is searchable and
consists of more than 400 redundant cancer expressions.
These are grouped into about 30 (mostly tissue-related)
categories. To explore the impact of a particular drug on
genes that are not just connected with cancer we
integrated cancer-unspeciﬁc information on interactions
provided by DrugBank (11). For ligands that are entries
in the NCI compound set ligand–protein interactions from
the Protein Data Bank (PDB) (18) were integrated into
CancerResource.
PubMed references are extracted for identiﬁed
compound–target relations to be cited in the web interface
(if available; otherwise the relation is referenced by linking
to the data resource by the resource’s identiﬁer).
(Drug-like) compounds and target genes
Core information of compounds and drugs was collected
from different databases like the Developmental
Therapeutics Program (DTP) at the NCI (12), PubChem
(19), SuperTarget (20) and SuperDrug (15).
CancerResource contains more than 40000 cancer-
relevant compounds.
The current set of target genes or proteins with cancer
relevance are conﬁrmed by the own text mining and com-
plemented by genes extracted from existing interaction
databases. The drug association is generally given (and
searchable) at gene level and, if available, additionally at
protein level. Core information on proteins and genes is
based on UniProt (21) and Ensembl (22). Supporting
information on cancer-relevant genes or proteins are
provided by ten of thousands protein–protein interactions
from ConsensusPathDB (23), afﬁliation of proteins to
more than a thousand protein complexes from the
Comprehensive Resource of Mammalian protein
complexes (CORUM) (24); hundreds of gene mutations
in NCI-60 tissue samples from COSMIC (4) and informa-
tion by Web Service requests or virtual data links to
iHOP, Reactome, Pfam and SYSTERS (25–28), see also
Supplementary Table S1.
KEGG pathways
To put compound–target relations into a cellular context,
we analyzed KEGG (signaling) pathways (29) according
to their relevance in cancer emergence and cancer devel-
opment. Forty four KEGG pathways were integrated into
the CancerResource environment. This set comprises
cancer-speciﬁc pathways, pathways related to cell-cycle
regulation, replication, immune response and drug metab-
olism. Pathway maps are dynamically retrieved via Web
Service from KEGG facultative with highlighted
expression data if gene expression is computed online
before. KEGG genes were excerpted from the set of
analyzed pathways and used in the gene vocabulary for
the text mining.
Cancer cell lines
Sixty human cancer cell lines of the NCI (NCI-60 set) were
selected with respect to the availability of expression data
as well as data of changes in biological activity by
compound treatment. (Human cancer cell lines and
cancer types are described in the Supplementary Data.)
Biological activity proﬁles: cellular ﬁngerprints
Biological activity proﬁles indicate the inﬂuence of com-
pounds on the growth rates of human cancer cell lines,
wherein a GI-50 value indicates the compound concentra-
tion that induces 50% growth inhibition after treatment.
More than 40 000 biological activity proﬁles are obtained
for each compound. All activity proﬁles are translated into
cellular ﬁngerprints which allow the fast computation (30)
of proﬁle differences.
D962 Nucleic AcidsResearch, 2011, Vol.39, Database issueGene expression data
Expression data of NCI-60 cancer cell lines were retrieved
from DTP at the NCI and re-calculated to be comparable
to external data sets in three steps (see Supplementary
Data). Over the whole microarray data set (Affymetrix
U133A chips), we introduced (i) the median normalization
on Affymetrix probe set expression and (ii) compared
normalized expression values of each probe set across
NCI-60 tissue samples by introducing the relative
abundance over all 60 cancer cell lines. Expression
intensities of probe sets are ignored if they are associated
with multiple genes. For each gene that is, according to
Ensembl, associated with multiple probe sets (iii) the
average of respective expression intensities is calculated.
Differential expression of genes after treatment
The Connectivity Map (31) provides differential expres-
sion data for ﬁve human cancer cell lines from the
NCI-60 set before and after treatment with more than
200 compounds. Data correspond to the Gene
Expression Omnibus (GEO) (32) data set GSE5258 and
ratios are retrieved by Web Service from the
GenomeMatrix repository (33), see also a detailed
description in (34).
RESULTS
Currently, CancerResource comprises more than 10 800
non-redundant compound–target relations. More than
6000 (56%) are associated with cancer and over 4700
relations from DrugBank that do not have a disease
speciﬁcation. However, integration of DrugBank data
enables high-quality searches for alternative targeting,
which is, in the context of pharmacogenomic research,
also known as drug repositioning. The CancerResource
literature text mining revealed 992 new compound–target
interactions (Table 1), which are 16% of the
cancer-related drug–target interactions or 10% of all
unique interactions in CancerResource. This ostensibly
low number is owing to mining abstract texts only. Even
after integration of our text mining results, the degree of
uniqueness for the CancerResource is still 90%, which
indicates that all four text mining strategies with focus on
cancer are obviously different to each other. In the whole
CancerResource interaction data set, 2392 cancer-related
target genes from CancerResource text mining, CTD,
PharmGKB and TTD and additionally 995 genes from
DrugBank cover 30% of the druggable genome (7); add-
itionally 728 cancer-related genes not present in the
druggable genome are found having compound–target
interactions. (More issues and numbers on integrated
data can be inspected in Supplementary Table S2.)
The integration of the set of more than 40000 NCI
compounds, dedicated as experimental drugs, extends
the set of Food and Drug Administration (FDA)
approved drugs by a factor of 100. It enriches
CancerResource as an information resource for better
understanding cancer and its treatment with drugs with
a huge experimental background.
MUTUAL ACCESS TO COMPOUNDS AND GENES
CancerResource provides the referencing to interaction
literature by links to citations in PubMed. In the web
interface, such relations can be accessed by a drug, a
target or a cancer feature; each of the three subjects can
be used to query the web tool. Both molecular instances,
target genes and drugs, can be mutually accessed (see
Figure 2a). Respective web pages are organized into
three parts that describe in detail (i) the relevance of a
drug or a gene to cancer, (ii) compound–target
interactions and (iii) supporting information.
At several sites in the web tool, interaction matrices of
compounds and target genes provide information on
single drugs targeting multiple genes (ambiguity) as well
as multiple drugs targeting a single gene (redundancy).
Such information on alternative targeting, which is
helpful for the potential repositioning of compounds, is
ampliﬁed through the integration of non-speciﬁc inter-
action information by DrugBank entries.
ACCESS TO EXPERIMENTAL DATA
Compound–target interaction information is more
valuable by integrating experimental and supporting
information. Therefore, CancerResource provides
experimental data in addition to the information on inter-
actions. Thereby, data stored in CancerResource can be
compared with the user’s own data. Several ways for
accessing the web tool are presented in this section.
Similarity of compounds by structure or biological activity
The inﬂuence of a compound on the growth of cancer cell
lines is a frequently used approach for the characterization
and development of drugs. The biological activity of two
compounds across the 60 NCI cell lines can be compared
by a similarity measure, the Tanimoto coefﬁcient of
cellular ﬁngerprints (30); this comparison by biological
characteristics of a compound is a strong feature of the
CancerResource web tool that complements the compari-
son of compounds by 2D structures. Here, the Tanimoto
coefﬁcient of structural ﬁngerprints (35) enables the
comparison of 2D similarities independently from the bio-
logical activity of a compound. CancerResource suggests
thereby substitutability, alternative compound applica-
tions and support thereby drug research and drug
treatment. Similar compounds are searchable by a given
activity proﬁle or the proﬁle of a particular compound
(query options are given in Figure 2b). Moreover,
activity proﬁles can be found for a given compound
structure.
Most active drugs against a cancer cell line
Alternatively to the compound characteristic deﬁned by
all cancer cell lines CancerResource enables the searching
for compounds that are most biologically active against a
single cell line (second part in Figure 3). In clinical
medicine, one of the most successful approach to treat
cancer is the growth inhibition of the cancer tissue.
Therefore, CancerResource implies a module to ﬁnd
Nucleic Acids Research, 2011,Vol.39, Database issue D963Figure 2. Knowledge retrieval in CancerResource: (a) Access to detailed compound/drug and target gene information in CancerResource. A similar
layout for both information layers, compounds (left) and target genes (right), comprises three information sections: (i) cancer relevance of a target
gene or a compound with KEGG cancer pathways, involved somatic cancer types, information on expression across cancer cell lines; (ii) information
on interactions with a toggle option between compound and target gene, source of information and link to the original literature source; (iii) speciﬁc
compound or gene information. (b) Access to complementary information on growth activity across NCI-60 human cancer cell lines and structures of
acting compounds. A search by compound structures (iv) reveals similar structures and associated growth activity proﬁles. The search by activity
proﬁles (v) enables the user to compare structure formulas, activity proﬁles (pairwise mean graphs) and similarity measures for both growth activity
and structures. Complementary queries can be performed by structures after downloading or by implemented links for a proﬁle.
D964 Nucleic AcidsResearch, 2011, Vol.39, Database issuemost effective compounds (that are inducing highest
inhibition) against a single cell line.
Gene expression data of NCI-60 cancer cell lines
In CancerResource, gene expression data are available for
about 4000 genes (see ‘Results’ section) and 60 NCI-60
cancer cell lines in both dimensions: genes are described
and can be compared by expression proﬁles, the arrays of
expression values across cell lines; NCI-60 cell lines are
described and can be compared by a proﬁle across
genes. Relative abundances (data are calculated online if
external data are uploaded) are displayed in the web tool
by an array of colored boxes, each corresponding to a
single gene. The blue/black/yellow color scheme is used
for lower/non-signiﬁcant/higher expression relatively to
the average across all cell lines.
Several entry points for expression data with respect to
genes are enabled: genes are searchable by the afﬁliation of
genes to KEGG pathways, afﬁliation to protein–protein
interaction data and for genes with low or high relative
abundance in a couple of cancer cell lines. Resulting
expression proﬁles over all 60 cell lines are characteristics
for genes. They can be ranked by similarity (Pearson’s
correlation) if a gene is selected as center; protein–
protein interactions and expression proﬁle similarity are
combined features here.
Furthermore, the NCI-60 cell line closest to a
user-deﬁned expression set (chip experiment; expression
data sets are compared by Pearson correlation) can be
searched both for genes (or probe sets) of a whole
microarray or for selected probe sets or genes.
Differential gene expression
CancerResource allows the genome-wide online validation
of two microarray chip experiments by computation of
differential expression via ratios. Either external data are
compared to a NCI-60 cell line or two external data sets
can be compared to each other. Normalization for a
subset of genes is regarded as a positive selection
feature. It is enabled in CancerResource, which hence
supports tumor/normal tissue comparisons or drug-
treatment/control experiments. Alternatively, pre-
calculated ratios associated with Ensembl gene IDs can
be uploaded to enable the import of results from other
experiment types (e.g. data collected using other micro-
array platforms, next generation sequencing, protein
chips, etc).
Ratios for differential expression are displayed in the
web tool by the green/black/red color scheme (down/
non-signiﬁcant/up). Arrays of colored boxes are
arranged according to the afﬁliation of respective genes
to chromosomes or KEGG pathways. For the latter,
differentially expressed genes are analyzed in order to
estimate the over-representation in a pathway. This is
calculated by a P-value using the hypergeometric
function and distribution, see details in (36).
Connectivity map
The Connectivity Map (31) was intended to aid the
discovery of functional connections among diseases,
genetic perturbation and drug action. The inﬂuence of
more than 200 compounds on differential gene expression
was determined for the whole genome of ﬁve cancer cell
lines. Two query options in CancerResource provide
access to expression proﬁles (i) for the inﬂuences of the
set of compounds in the ﬁve cell lines on a single gene and
(ii) for the inﬂuence of a single compound on all genes in a
single cell line. The visualization, again by arrays of
colored boxes, is restricted to target genes that possess
interactions integrated in CancerResource.
Direct and indirect knowledge on compound–target
interaction
In the Connectivity Map data set, the inﬂuence of a row of
compounds on genes is experimentally studied by differ-
ential expression, which is indirect knowledge about gene
targeting (but no about cause-and-effect relationships).
The simultaneous comparison (Supplementary Figure
S1) with compound–target interactions from the literature
mining (‘direct knowledge’) facilitates considerations
about druggability and targeting of genes.
PROPOSED WORKFLOWS
CancerResource facilitates complex searches by the
implementation of several ways of accessing the data.
Two workﬂows are demonstrating suggested research
use cases.
Finding alternative, most effective drugs for a (somatic)
tissue similar to a cancer cell line
An external tissue sample can be identiﬁed as most similar
to a single NCI-60 cell line by expression proﬁles across
genes or probe sets. Figure 3 explains how the most
similar (‘best’) NCI-60 cell line can be determined with
differentially expressed genes by calculation of Pearson
correlations between the upload data and all 60 tissues
samples (see above). In the next step, the most effective
drugs will be determined for this cell line (which is basing
on the growth inhibition of a compound is measured for
all NCI-60 cancer cell lines and is described above).
Finally, for the identiﬁed compounds the tool displays
the genes they target including the alternative targeting.
Finding alternative compound–target gene interactions for
differentially expressed genes via pathway information
KEGG (signaling) pathways elucidate the context of genes
according to functionality. To visualize the differential
regulation of genes in a pathway, colored pathway maps
are dynamically generated in CancerResource. The
workﬂow starts with the loading of expression data
(Supplementary Figure S2), which is possible in multiple
forms. The data are re-calculated and displayed as an
array of colored boxes for each KEGG pathway;
overrepresentation analyses are available for each
pathway and for both up- and down-regulated genes;
the pathway map generation can be started from here to
display integrated expression of genes, either for a single
gene or for all genes in the pathway. Finally, drug
information is available (via the pathway map) and,
Nucleic Acids Research, 2011,Vol.39, Database issue D965subsequently, the compound–target matrix for alternative
targeting. The integration of dynamically assigned
pathway maps makes CancerResource into a systems
biology approach.
CONCLUSIONS AND FUTURE DIRECTIONS
The feedback by many scientists shows that there is a
need for specialized resources that not only cover a
speciﬁc set of interaction data but also deliver tools
that are specialized for the further analysis of the respect-
ive data set. CancerResource tries to cover both levels of
scientiﬁc work, the support of scientists who try to
develop novel drugs and the medic who is reliant on
advice for the development of individualized therapy
approaches.
Cancers, even of the same tissue type, are extremely
divergent in terms of gene alterations. Individual therapy
will be made possible by understanding single nucleotide
polymorphisms (SNPs), complete or partial gene
deletions, copy number variations, gene aberrations or
gene fusions. All of those issues may cause substantial
dysfunctions of defected genes that have inﬂuence on
gene regulation in the whole cell of an individual.
Additionally to those integration issues, new data integra-
tion concepts will be required or are planned to be
integrated in CancerResource for coping with
personalized therapies. The literature mining will be
extended to full text mining, manual upload of single
relationships and enhanced speciﬁcity in cancer annota-
tions. Expression data will be comparable for platforms
other than Affymetrix U133A. Large studies performed
on the basis of new techniques (Next Generation
Sequencing; e.g. Genetics of 1000 Tumors) are highly
interesting objectives to be made available in
CancerResource. Updating of data is projected to occur
once a year.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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